DATE: December 10, 2018 Intent to Testify and Testimony Summary/Comments on Negotiating Objectives for a U.S.-European Union Trade Agreement (USEUTA) Luis Gil Abinader. Knowledge Ecology International 1621 Connecticut Avenue, Northwest, Suite 500, Washington, DC 20009. Phone number +1.202.332.2670. Federal Register… Continue Reading
On Monday, 3 December 2018, Knowledge Ecology International (KEI) delivered this opening statement at WIPO’s 29th Session of the Standing Committee on the Law of Patents (SCP). Thank you Chair. KEI welcomes the conclusions of SCP 28 which call upon… Continue Reading
DATE: Thursday, 6 December 2018 TIME: 1:30 PM to 3 PM VENUE: Room B CONVENER: Knowledge Ecology International (KEI) Knowledge Ecology International (KEI) cordially invites you to attend our side event during negotiations of the 29th Session of the Standing… Continue Reading
The United States-Mexico-Canada Agreement (USMCA) provisions on the term of protection of test data for new pharmaceutical products has received considerable attention, and in some cases, some inaccurate reports on the agreement have conflated the term for test data protection… Continue Reading
On Tuesday, 25 September 2018, Knowledge Ecology International delivered the following opening statement at the 2018 WIPO General Assembly. Opening Statement, Knowledge Ecology International KEI would like WIPO to continue work on, and evaluate the progress of, the obligation that… Continue Reading
On Thursday, 20 September 2018, Knowledge Ecology International (KEI) delivered the following statement in Rome during discussions at the WHO Regional Committee for Europe on the WHO Roadmap on Access to Medicines and Vaccines. Oral statement of Knowledge Ecology International… Continue Reading
On August 20, 2018, KEI filed comments in response to the US Federal Trade Commission’s hearings and public comment process to address, “Competition and Consumer Protection in the 21st Century.” The goal of the process is to examine, “whether broad-based… Continue Reading
The following are comments by the KEI on the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, in response to notice in the Federal Register, 83 FR 22692. Overall, the Blueprint is very weak, and won’t do much… Continue Reading
On April 19, 2018, KEI filed a lawsuit against the NIH license of CD30 CAR T patents to Gilead. On April 11, 2019, the lawsuit was dismissed on the grounds that KEI lacked standing. KEI blogs January 5, 2018. 2018: Briefing note… Continue Reading
On Monday, 9 July 2018, Knowledge Ecology International (KEI) made the following statement on exceptions and limitations to patent rights. KEI made the following proposal: In terms of future work on this item on exceptions and limitations to patent rights,… Continue Reading